urinary%20incontinence
URINARY INCONTINENCE
Urinary incontinence is the complaint of involuntary urine leakage.
Stress urinary incontinence is the involuntary urine leakage on effort or exertion or when coughing or sneezing.
Urge urinary incontinence is the one associated with or immediately preceded by urgency.
Mixed urinary incontinence is the involuntary urine leakage associated with both urgency and with exertion, effort, coughing or sneezing.

Urinary%20incontinence Management

Monitoring

Consider immediate referral to a specialist in the following conditions:

  • Incontinence w/ abdominal &/or pelvic pain
  • Hematuria in the absence of an infection
  • Suspected fistula
  • Complex neurological conditions (eg Parkinson’s disease, spinal cord injury)
  • Abnormal findings (eg pelvic mass or symptomatic organ prolapse beyond the hymen)

Consider elective referral to a specialist in the following conditions:

  • Persistent symptoms after an adequate therapeutic trial
  • Uncertain diagnosis & lack of reasonable treatment plan
  • Significant increase in PVRV that does not resolve after treatment of possible precipitants (eg medications, stool impaction)
  • Prior pelvic surgery or pelvic irradiation
  • Desire for surgical treatment
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 2 days ago
Adding dapagliflozin to standard of care (SOC) significantly reduces the risk of worsening kidney function, death due to kidney or cardiovascular (CV) disease, and all-cause mortality compared with SOC alone in patients with chronic kidney disease (CKD), regardless of whether they have type 2 diabetes (T2D), reveals the DAPA-CKD* trial — showing dapagliflozin charting new territories from diabetes to the renal realm.
Roshini Claire Anthony, 2 days ago

In patients with chronic heart failure with reduced ejection fraction (HFrEF), empagliflozin reduced the risk of cardiovascular (CV) death or heart failure hospitalization (HHF) and decline in estimated glomerular filtration rate (eGFR), results of the EMPEROR-Reduced* trial showed.